Clinical trials: Preserved Ejection Fraction
Heart Failure, Systemic Inflammation
A Research Study Looking Into How Ziltivekimab Works Compared to Placebo in Participants With Heart Failure and Inflammation
The study is being done to see if ziltivekimab can be used to treat participants living with heart failure and inflammation. Participants will either get ziltivekimab (active medicine) or placebo (inactive substance that looks…
- Trial name
- ATHENA (NCT06200207)
- Testing
- Ziltivekimab
- Where
- 217 sites in United States, Argentina and 14 more
- Volunteers
- 673 people
- Sponsor
- Novo Nordisk A/S
Heart Failure With Preserved Ejection Fraction
Endovascular GSN Ablation in Subjects With HFpEF
The purpose of this study is to evaluate the safety and potential benefits of single-side block of a nerve that connects to the intestines, liver and spleen called the "greater splanchnic nerve" for the treatments of patients…
- Trial name
- NCT04287946
- Testing
- Ablation
- Where
- 3 sites in Czechia, Georgia
- Volunteers
- 30 people
- Sponsor
- Axon Therapies, Inc.
Heart Failure
A Trial to Study Neladenoson Bialanate Over 20 Weeks in Patients With Chronic Heart Failure With Preserved Ejection Fraction
The objective of the study is to find the optimal dose of once daily oral neladenoson bialanate (BAY1067197) when given in addition to appropriate therapy for specific comorbidities.
- Trial name
- PANACHE (NCT03098979)
- Testing
- Neladenoson bialanate (BAY1067197)
- Where
- 76 sites in United States, Austria and 10 more
- Volunteers
- 305 people
- Sponsor
- Bayer
Heart Failure With Preserved Ejection Fraction, Prognathism
Effect of Bilirubin on Prognosis in Heart Failure With Preserved Ejection Fraction
Factors influencing the prognosis of patients with heart failure with preserved ejection fraction (HFpEF) have been extensively studied.
- Trial name
- NCT06379152
- Where
- China
- Volunteers
- 400 people
- Sponsor
- Chongqing Medical University
Heart Failure With Preserved Ejection Fraction, Left Ventricular Diastolic Dysfunction
Invasive Left Heart Catheterization Registry
Retrospectively enrolled suspicious of heart failure with preserved ejection fraction (HFpEF) patients who underwent left heart catheterization with the measurement of left ventricular end-diastolic pressure.
- Trial name
- NCT04505449
- Testing
- Left heart catheterization
- Where
- South Korea
- Volunteers
- 404 people
- Sponsor
- Samsung Medical Center
Heart Failure With Preserved Ejection Fraction, Atrial Fibrillation, Persistent
Atrioventricular Node Ablation and Conduction System Pacing in Patients With Well Controlled Permanent Atrial Fibrillation (AF), Heart Failure and Preserved Ejection Fraction: Heart Rate Regularization Versus Medical Rate Control
The goal of this clinical trial is to assess the clinical efficacy of physiological pacing combined with atrioventricular node ablation, in patients with Heart Failure with preserved Ejection Fraction (HFpEF) and well controlled…
- Trial name
- HF-RELIEF (NCT06833138)
- Testing
- pacemaker implantation, atrioventricular node ablation, Pacemaker programming
- Where
- 17 sites in France
- Volunteers
- 266 people
- Sponsor
- French Cardiology Society
Type 2 Diabetes, Heart Failure
Comparative Effectiveness of Oral Semaglutide vs Sitagliptin Among Individuals With Heart Failure With Preserved Ejection Fraction (STEP-HFpEF DM ORAL)
Investigators are building an empirical evidence base for real world data through large-scale emulation of randomized controlled trials.
- Trial name
- NCT07390110
- Testing
- Oral semaglutide, Sitagliptin
- Where
- United States
- Volunteers
- 25,664 people
- Sponsor
- Brigham and Women's Hospital
Heart Failure Low Output, Heart Failure
The Prelieve Trial - Pilot Study to Assess Safety and Efficacy of a Novel Atrial Flow Regulator (AFR) in Heart Failure Patients
This study aims to investigate safety and efficacy of the Occlutech® AFR device in patients with HFrEF (Heart failure with reduced ejection fraction) and HFpEF (Heart failure with preserved ejection fraction)
- Trial name
- PRELIEVE (NCT03030274)
- Testing
- Occlutech AFR device
- Where
- 26 sites in Belgium, Germany and 1 more
- Volunteers
- 106 people
- Sponsor
- Occlutech International AB
HFpEF
Predictors of Poor Prognosis in HFpEF
Patients with HFpEF who have undergone meticulous clinical and instrumental evaluation (including diastolic exercise testing) between 2013 and 2020, will be followed up for at least 3 years.
- Trial name
- NCT06844032
- Where
- Russia
- Volunteers
- 500 people
- Sponsor
- National Medical Research Center for Cardiology, Ministry of Health of Russian Federation
Adults With Heart Failure, Mild Decrease in Ejection Fraction/Preserved Ejection Fraction, and Obesity
Study on the Efficacy and Safety of HRS-7535 in Patients With Mild Decrease in Ejection Fraction/Preserved Ejection Fraction Heart Failure and Obesity
This is a multicenter, randomized, double-blind, placebo-controlled, parallel design phase II clinical trial, including a screening period of up to 2 weeks, a 36-weeks' treatment period, and a 1-week safety follow-up visit period.
- Trial name
- NCT06820099
- Testing
- HRS-7535 tablet
- Where
- China
- Volunteers
- 225 people
- Sponsor
- Shandong Suncadia Medicine Co., Ltd.
Diastolic Heart Failure
Pedometer-Based Walking Intervention in Patients With Chronic Heart Failure With Preserved Ejection Fraction
A multicenter randomized controlled trial, with follow-up at 6 and 12 months. Physically inactive participants with chronic heart failure with preserved or mid-range ejection fraction will be randomly assigned to intervention or…
- Trial name
- NCT03041376
- Testing
- Walking intervention
- Where
- Czechia
- Volunteers
- 200 people
- Sponsor
- Charles University, Czech Republic
Heart Failure With Preserved Ejection Fraction, Coronary Microvascular Dysfunction
Distribution and Clinical Implication of CMD in Patients With HFpEF Without Significant CAD
To evaluate the incidence of coronary microvascular dysfunction (CMD) and its' prognostic implication in patients who have diagnosed as heart failure with preserved ejection fraction (HFpEF) confirmed by HFA-PEFF scoring system…
- Trial name
- HFpEF-CMD (NCT04788576)
- Testing
- Invasive physiologic evaluation (fractional flow reserve, coronary flow reserve, index of microcirculatory resistance)
- Where
- South Korea
- Volunteers
- 100 people
- Sponsor
- Samsung Medical Center
Heart Failure With Preserved Ejection Fraction
HRS9531 Injection in Obese Subjects With Heart Failure With Preserved Ejection Fraction
This was a multicenter, randomized, double-blind, placebo-parallel-controlled Phase II clinical study to evaluate the efficacy and safety of HRS9531 Injection compared to placebo in obese subjects with heart failure with…
- Trial name
- NCT06391710
- Testing
- HRS9531
- Where
- China
- Volunteers
- 203 people
- Sponsor
- Fujian Shengdi Pharmaceutical Co., Ltd.
Heart Failure With Preserved Ejection Fraction (HFPEF)
Hearts on Fire: Targeting Inflammation in Heart Failure With Preserved Ejection Fraction
Subjects undergo a gadolinium-based CMR followed by an iron infusion and then a repeat CMR in 72 hours
- Trial name
- NCT07634640
- Testing
- Ferumoxytol infusion
- Where
- United States
- Volunteers
- 70 people
- Sponsor
- University of Florida
Diastolic Heart Failure, Heart Failure With Preserved Ejection Fraction
Purinergic Signaling and the Postmenopausal Heart
There is an increased risk of diastolic heart failure in post menopausal women. Estrogen plays a positive role in regulating molecular pathways in heart remodeling.
- Trial name
- NCT06015776
- Testing
- Gender
- Where
- United States
- Volunteers
- 500 people
- Sponsor
- Beth Israel Deaconess Medical Center
Heart Failure With a Preserved Ejection Fraction, Heart Failure, Diastolic
Efficacy Study of Pacemakers to Treat Slow Heart Rate in Patients With Heart Failure
Determine the impact of restoring normal heart rate response during exercise and daily activity in patients with heart failure and a preserved ejection fraction (HFpEF) and chronotropic incompetence (CI).
- Conditions
- Heart Failure With a Preserved Ejection Fraction, Heart Failure, Diastolic, Chronotropic Incompetence
- Trial name
- RAPID-HF (NCT02145351)
- Testing
- Rate adaptive atrial pacing using a dual-chamber pacemaker, Pacemaker system will be implanted but set to Pacing Off.
- Where
- United States
- Volunteers
- 32 people
- Sponsor
- Mayo Clinic
Heart Failure
Heart Failure Evaluation Study
Heart failure (HF) is a highly prevalent conditions that impose a significant burden to the patients, the hospital and the healthcare system. In Hong Kong, HF was one of the commonest causes of hospitalization and death.
- Trial name
- NCT05583513
- Testing
- MLHFQ (Minnesota Living with Heart Failure Questionnaire), KCCQ (the Kansas City Cardiomyopathy Questionnaire)
- Where
- Hong Kong
- Volunteers
- 500 people
- Sponsor
- Chinese University of Hong Kong
Cardiac Amyloidosis, Heart Failure With Preserved Ejection Fraction
Cardiac Amyloidosis in HFpEF Tunisian Patients
Cardiac amyloidosis (CA) has recently been reported as a common cause of heart failure with preserved left ventricular ejection fraction (HFpEF), with a prevalence of 6% in elderly HFpEF patients.
- Conditions
- Cardiac Amyloidosis, Heart Failure With Preserved Ejection Fraction, Echocardiography, CMR
- Trial name
- Amy-Card (NCT06201832)
- Where
- Tunisia
- Volunteers
- 87 people
- Sponsor
- University Tunis El Manar
Heart Failure with Preserved Ejection Fraction
"HerzCheck" - Detection of Early Heart Failure Using Telemedicine in Structurally Weak Regions
This study is intended to provide a basis for decision-making for the improved medical care of patients with asymptomatic heart failure, especially in structurally weak regions.
- Trial name
- NCT05122793
- Testing
- Prevention offer
- Where
- Germany
- Volunteers
- 4,509 people
- Sponsor
- German Heart Institute
Heart Failure, Preserved Ejection Fraction
Randomized Double-blind Controlled Clinical Study of SGLT-2i Combined With Probiotic Preparations in Elderly Patients With HFpEF
HFpEF has a high incidence and lacks effective therapy, and its onset is closely related to systemic inflammation and intestinal dysbacteriosis.SGLT-2i exerts its effects by diuresis, anti-inflammatory and improving energy…
- Trial name
- NCT07687212
- Testing
- Henggliflozin Combined with Probiotics, Henggliflozin
- Where
- China
- Volunteers
- 162 people
- Sponsor
- The First Affiliated Hospital of Air Force Medical University